Researchers from Massachusetts General Hospital and Harvard University have discovered a possible new mechanism to halt the disease process in Alzheimer's.
For the first time, scientists have genetically engineered a lab rat that has the full range of brain changes associated with Alzheimer's disease--that is, it more accurately mirrors the brain of a person with the disease.
Close to six years after promising up to $500 million to gain rights to Zurich-based Cytos Biotechnology's ($CYTN) smoking cessation vaccine, Novartis has handed back the rights to the treatment and written off its investment.
Eli Lilly's ($LLY) solanezumab has secured an endorsement from Alzheimer's researchers, who will study the experimental drug as a preventive therapy against the memory-robbing disease in patients before symptoms emerge.
While the cause of Alzheimer's disease continues to elude scientists, a new compound carries the promise of restoring memory loss and reversing the symptoms of the disease.
Scientists in two different studies identified what is now only the second known gene mutation suspected to increase the likelihood of Alzheimer's disease in senior citizens.
In the two pivotal Phase III studies of the drug, investigators determined that there was a noticeable effect on the level of beta amyloid found in patients' blood, suggesting that solanezumab had reduced levels of the toxic protein in the brain.
The Alzheimer's drug bapineuzumab failed miserably in one of the biggest Phase III studies of the year. But the drug--once a megablockbuster hopeful at Johnson & Johnson and Pfizer--had an impact on key biomarkers for the disease, leading investigators to urge a major new effort to see if the drug could work to delay the onset of the memory-wasting affliction.
Researchers say they've made preclinical progress on a tantalizingly simple approach to fighting Alzheimer's disease. By eliminating a single enzyme in symptomatic mice, they drastically reduced the amount of plaque that is a hallmark of the disease's advance. And the rodents' cognitive abilities improved as a result.
Alzheimer's disease research is at a pivotal point. Researchers are turning away from diagnosed groups and starting to move upstream, anxious to see if new therapies can prevent the disease from occurring or if very early-stage Alzheimer's patients might respond.